Skip to main content

Advertisement

SpringerLink
Log in

Liquid Biopsy Applications in the Clinic

  • Current Opinion
  • Published:
Molecular Diagnosis & Therapy Aims and scope Submit manuscript

A Correction to this article was published on 17 February 2020

This article has been updated

Abstract

The global liquid biopsy industry is expected to exceed $US5 billion by 2023. One application of liquid biopsy technology is the diagnosis of disease using biomarkers found in blood, urine, stool, saliva, and other biological samples from patients. These biomarkers could be DNA, RNA, protein, or even a cell. More recently, the use of cell-free DNA from plasma is emerging as an important minimally invasive tool for clinical diagnosis. The development of technology has increased the diversity of its application. Here, we discuss how liquid biopsies have been used in the clinic, and how personalized medicine are likely to use liquid biopsies in the near future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Change history

  • 17 February 2020

    In the original publication of the article, the name of the fourth author, which previously read "Howard Chan”, should read as "Howard Chang". The original article has been updated.

References

  1. Reportlinker. New York. https://www.prnewswire.com/news-releases/global-liquid-biopsy-market-outlook-to-2020-300220260.html (2016).

  2. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14:531.

    Article  CAS  PubMed  Google Scholar 

  3. Ashworth T. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J. 1869;14:146.

    Google Scholar 

  4. Krebs MG, Hou JM, Ward TH, Blackhall FH, Dive C. Circulating tumour cells: their utility in cancer management and predicting outcomes. Ther Adv Med Oncol. 2010;2:351–65. https://doi.org/10.1177/1758834010378414.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 2014;4:650–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Neumann MHD, Bender S, Krahn T, Schlange T. ctDNA and CTCs in liquid biopsy—current status and where we need to progress. Comput Struct Biotechnol J. 2018;16:190–5.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Bidard F-C, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, et al. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. J. Natl. Cancer Inst. 2018;110:560–7.

    Article  PubMed  Google Scholar 

  8. Potdar PD, Sen K. Profiling of circulating tumor cells in liquid biopsies from metastatic cancer patients. J Cancer Metastasis Treat. 2017;3:6–15.

    Article  CAS  Google Scholar 

  9. Pan B-T, Johnstone RM. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell. 1983;33:967–78.

    Article  CAS  PubMed  Google Scholar 

  10. Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and α-granules. Blood. 1999;94:3791–9.

    Article  CAS  PubMed  Google Scholar 

  11. Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. J Proteomics. 2010;73:1907–20.

    Article  CAS  PubMed  Google Scholar 

  12. Stevens GL, Scheer WD, Levine EA. Detection of tyrosinase mRNA from the blood of melanoma patients. Cancer Epidemiol Biomark Prev. 1996;5:293–6.

    CAS  Google Scholar 

  13. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008;110:13–21. https://doi.org/10.1016/j.ygyno.2008.04.033.

    Article  CAS  PubMed  Google Scholar 

  14. Otandault A, Anker P, Al Amir Dache Z, Guillaumon V, Meddeb R, Pastor B, Pisareva E, Sanchez C, Tanos R, Tousch G, et al. Recent advances in circulating nucleic acids in oncology. Ann. Oncol. 2019;30:374–84.

    Article  CAS  PubMed  Google Scholar 

  15. Zhang X, Hong R, Chen W, Xu M, Wang L. The role of long noncoding RNA in major human disease. Bioorg Chem. 2019;92:103214.

    Article  CAS  PubMed  Google Scholar 

  16. Bach DH, Lee SK, Sood AK. Circular RNAs in cancer. Mol Ther Nucleic Acids. 2019;16:118–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Pastorino U, Boeri M, Sestini S, Sabia F, Silva M, Suatoni P, Verri C, Cantarutti A, Sverzellati N, Corrao G, Marchianò A, Sozzi G. Blood microRNA and LDCT reduce unnecessary LDCT repeats in lung cancer screening: results of prospective BioMILD trial. International Association for the Study of Lung Cancer, World Conference on Lung Cancer (2019).

  18. Mandel P, Metais P. Title in other language. C R Seances Soc Biol Fil. 1948;142:241–3.

    CAS  PubMed  Google Scholar 

  19. Wan JC, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17:223.

    Article  CAS  PubMed  Google Scholar 

  20. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer. 2002;2:210.

    Article  CAS  PubMed  Google Scholar 

  21. Underhill HR, et al. Fragment length of circulating tumor DNA. PLoS Genet. 2016;12:e1006162.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32:579.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Köhn L, Johansson M, Grankvist K, Nilsson J. Liquid biopsies in lung cancer—time to implement research technologies in routine care? Ann Transl Med. 2017;5:278.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Lo YM, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350:485–7. https://doi.org/10.1016/s0140-6736(97)02174-0.

    Article  CAS  PubMed  Google Scholar 

  25. Canick JA, Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE. The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies. Prenat Diagn. 2013;33:667–74. https://doi.org/10.1002/pd.4126.

    Article  CAS  PubMed  Google Scholar 

  26. Hui L, Bianchi DW. Noninvasive prenatal DNA testing: the vanguard of genomic medicine. Annu Rev Med. 2017;68:459–72. https://doi.org/10.1146/annurev-med-072115-033220.

    Article  CAS  PubMed  Google Scholar 

  27. Suciu ID, Toader OD, Galeva S, Pop L. Non-invasive prenatal testing beyond trisomies. J Med Life. 2019;12:221–4.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Taylor-Phillips S, et al. Accuracy of non-invasive prenatal testing using cell-free DNA for detection of Down, Edwards and Patau syndromes: a systematic review and meta-analysis. BMJ Open. 2016;6(1):e010002.

    Article  PubMed  PubMed Central  Google Scholar 

  29. FDA. List of cleared or approved companion diagnostic devices (in vitro and imaging tools) (2018).

  30. Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O’Connell A, Messineo MM, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res. 2014;20(6):1698–705.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Denis JA, Guillerm E, Coulet F, Larsen AK, Lacorte JM. The role of BEAMing and digital PCR for multiplexed analysis in molecular oncology in the era of next-generation sequencing. Mol Diagn Ther. 2017;21(6):587–600.

    Article  CAS  PubMed  Google Scholar 

  32. Olmedillas-López S, García-Arranz M, García-Olmo D. Current and emerging applications of droplet digital PCR in oncology. Mol Diagn Ther. 2017;21(5):493–510.

    Article  CAS  PubMed  Google Scholar 

  33. TaqMan™ Liquid Biopsy dPCR Assay. https://www.thermofisher.com/order/catalog/product/A44177?SID=srch-hj-A44177#/A44177?SID=srch-hj-A44177. Accessed 30 Dec 2019.

  34. Baer C, Kern W, Koch S, Nadarajah N, Schindela S, Meggendorfer M, Haferlach C, Haferlach T. Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation t315i in chronic myeloid leukemia. Haematologica. 2016;101(7):830–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Chen M, Zhao H. Next-generation sequencing in liquid biopsy: cancer screening and early detection. Hum Genomics. 2019;13(1):34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, Anagnostou V, Fiksel J, Cristiano S, Papp E, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017;9(403):eaan2415.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Razavi P, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med. 2019;25(12):1928–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Oncomine™ Pan-Cancer Cell-Free Assay. https://www.thermofisher.com/order/catalog/product/A37664?SID=srch-srp-A37664#/A37664?SID=srch-srp-A37664. Accessed 30 Dec 2019.

  39. AVENIO ctDNA Analysis Kits. https://sequencing.roche.com/en-us/products-solutions/by-category/assays/ctdna-analysis-kits.html. Accessed 30 Dec 2019.

  40. TruSight Oncology 500 ctDNA. https://www.illumina.com/products/by-type/clinical-research-products/trusight-oncology-500-ctdna.html. Accessed 30 Dec 2019.

  41. Cohen JD et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science eaar3247 (2018).

  42. Chan KA, et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med. 2017;377:513–22.

    Article  CAS  PubMed  Google Scholar 

  43. Tie J, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8:346ra392-346ra392.

    Article  CAS  Google Scholar 

  44. Garcia-Murillas I, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Science translational medicine. 2015;7:302ra133-302ra133.

    Article  Google Scholar 

  45. Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proc Natl Acad Sci. 2003;100:776–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Brahmer JR, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Chalmers ZR, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Gandara DR, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24:1441.

    Article  CAS  PubMed  Google Scholar 

  49. Liu XS, Mardis ER. Applications of immunogenomics to cancer. Cell. 2017;168:600–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Garcia-Garijo A, Fajardo CA, Gros A. Determinants for neoantigen identification. Front Immunol. 2019. https://doi.org/10.3389/fimmu.2019.01392.

    Article  PubMed  Google Scholar 

  51. Nielsen M, et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. 2003;12:1007–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Lundegaard C, et al. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8–11. Nucleic Acids Res. 2008;36:W509–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Lundegaard C, Lund O, Nielsen M. Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. Bioinformatics. 2008;24:1397–8.

    Article  CAS  PubMed  Google Scholar 

  54. Merker JD, Oxnard GR, Compton C, et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review. Arch Pathol Lab Med. 2018;142:1242–53.

    Article  CAS  PubMed  Google Scholar 

  55. Benincasa G, Mansueto G, Napoli C. Fluid-based assays and precision medicine of cardiovascular diseases: the ‘hope’ for Pandora’s box? J Clin Pathol. 2019;72(12):785–99.

    Article  PubMed  Google Scholar 

  56. Zhang X, Karunathilaka N, Senanayake S, Subramaniam VN, Chan W, Kostner K, Fraser J, Atherton JJ, Punyadeera C. The potential prognostic utility of salivary galectin-3 concentrations in heart failure. Clin Res Cardiol. (2019). https://doi.org/10.1007/s00392-019-01557-0(epub ahead of print).

  57. Lehmann-Werman R, Neiman D, Zemmour H, et al. Identification of tissue-specific cell death using methylation patterns of circulation DNA. Proc Natl Acad Sci USA. 2016;113(13):E1826–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Roels S, Costa OR, Tersey SA, Stangé G, De Smet D, Balti EV, Gillard P, Keymeulen B, Ling Z, Pipeleers DG, Gorus FK, Mirmira RG, Martens GA. Combined analysis of GAD65, miR-375, and unmethylated insulin DNA following islet transplantation in patients with T1D. J Clin Endocrinol Metab. 2019;104(2):451–60.

    Article  PubMed  Google Scholar 

  59. Lim B, Tsolaki M, Soosaipillai A, Brown M, Zilakaki M, Tagaraki F, Fotiou D, Koutsouraki E, Grosi E, Prassas I, Diamandis EP. Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer’s disease. Clin Chem Lab Med. 2019;57(12):1875–81.

    Article  CAS  PubMed  Google Scholar 

  60. Frost & Sullivan, Growth opportunities in the global liquid biopsy market, (2018).

Download references

Funding

Paper is supported by the Shenzhen Science and Technology programs (Grant no. JCYJ20150529151839281), the Guangdong Natural Science Foundation (Grant no. 2016A030313381), and the Shenzhen Health and Family Planning Commission (Grant no. SZSM201612041) to S.W. and Y.Z.

Author information

Author notes

  1. Dake Chen and Tao Xu contributed equally to this work.

Authors and Affiliations

  1. Department of Oncology, Tongzhou People’s Hospital, Nantong, 226300, China

    Dake Chen

  2. Department of Anesthesiology, Affiliated Shanghai Sixth People’s Hospital, Shanghai Jiao Tong University, Shanghai, 200233, China

    Tao Xu

  3. Department of Oncology, Peking University-Shenzhen Hospital, Shenzhen, China

    Shubin Wang & Yu Zhu

  4. CuraCloud Corporation, 999 Third Ave, Suite 700, Seattle, WA, 98104, USA

    Howard Chang & Tao Yu

  5. Department of Orthopedics, Tongzhou People’s Hospital, Nantong, 226300, China

    Jian Chen

Authors
  1. Dake Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tao Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shubin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Howard Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tao Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yu Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jian Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Tao Yu, Yu Zhu or Jian Chen.

Ethics declarations

Conflict of interest

Dake Chen, Tao Xu, Shubin Wang, Howard Chang, Tao Yu, Yu Zhu, and Jian Chen have no conflicts of interest that are directly relevant to the content of this review/study.

Additional information

The original version of this article was revised as the name of the fourth author, which previously read “Howard Chan”, should read as “Howard Chang”.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, D., Xu, T., Wang, S. et al. Liquid Biopsy Applications in the Clinic. Mol Diagn Ther 24, 125–132 (2020). https://doi.org/10.1007/s40291-019-00444-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40291-019-00444-8

Search

Navigation